OTC Monographs Face Obsolescence In Shadow Of NDA Products
This article was originally published in The Tan Sheet
Executive Summary
Many monograph OTCs are overshadowed in the marketplace by NDA products and have much less space on store shelves. With some NDA-approved ingredients moved to monographs, FDA pre-market approval would no longer be required and more firms could make those products.
You may also be interested in...
CHPA Regulatory & Scientific Conference In Brief
OTC monograph finalization may never end, FDA exec suggests; agency official advises coloring inside the monograph lines; OTC adverse event reports fell about 19% in 2011; supplement AER practices can mitigate rising insurance rates.
Guidance Underscores FDA Practice Of Letting TEAs Steep
The viability of time and extent applications as a route to market for new OTC ingredients continues to wane in light of new final guidance on the process.
Regulatory News In Brief
Ephedrine-tainted herbals recalled